Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy

[PR Newswire] – “Significant unmet medical need exists in many prevalent autoimmune diseases where individual patient needs are not adequately being met with available treatments,” said Thomas Bumol, Ph.D., senior vice president, biotechnology . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy Similar Articles: Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis Company Update (NYSE:LLY): Lilly delays submission to market once-daily diabetes drug Stock Update (NYSE:LLY): Lilly to Participate in Credit Suisse 2014 Healthcare Conference